Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial
Ellen M. Apperloo(University Medical Center Groningen), José Luis Górriz(INCLIVA Health Research Institute), María José Soler(Vall d'Hebron Institut de Recerca), Secundino Cigarrán Guldris(Hospital Universitario Lucus Augusti), Josep M. Cruzado(Bellvitge University Hospital), María Jesús Puchades(INCLIVA Health Research Institute), Marina López-Martínez(Vall d'Hebron Institut de Recerca), Femke Waanders(Isala), Gozewijn D. Laverman(Ziekenhuis Groep Twente), Annemarie van der Aart-van der Beek(Martini Ziekenhuis), Klaas Hoogenberg(Martini Ziekenhuis), André P. van Beek(University Medical Center Groningen), Jacobien C. Verhave(Rijnstate Hospital), Sofia B. Ahmed(University of Alberta), Roland E. Schmieder(Friedrich-Alexander-Universität Erlangen-Nürnberg), Christoph Wanner(Universitätsklinikum Würzburg), David Z.I. Cherney(University of Toronto), Niels Jongs(University Medical Center Groningen), Hiddo J.L. Heerspink(University Medical Center Groningen)
Cited by 93Open Access
Abstract
Related Papers
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John Wilding, Rachel L. Batterham, Salvatore Calanna et al.|New England Journal of Medicine|2021|4.3k
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Katherine R Tuttle, Mark Lakshmanan, Brian Rayner et al.|The Lancet Diabetes & Endocrinology|2018|631